The Evolving Evidence for the Long-Term, Prophylactic Treatment of Hereditary Angioedema Patients with Subcutaneous C1-INH
The Evolving Evidence for the Long-Term, Prophylactic Treatment of Hereditary Angioedema Patients with Subcutaneous C1-INH
Welcome and Introduction
Marcus Maurer
Learnings from the HAE Guidelines
Markus Magerl
Examining the Evidence Regarding C1-INH (SC) in All Populations, with an Emphasis on Special Populations
Donald Levy
Using Clinical and Real-World Experience to Inform Treatment Decisions
Stefan Cimbollek
Q&A Session
Markus Magerl, Marcus Maurer, Donald Levy, Stefan Cimbollek
Summary and close
Marcus Maurer